Related Experiment Video
Updated: May 23, 2026
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
[Effect of early high-loading-dose tirofiban on platelet activity in patients with acute ST-segment elevation
Xiao-nan Ren1, Le-feng Wang, Ming-sheng Wang
1Capital Medical University, Beijing, China.
Insights
Early high-loading-dose tirofiban significantly enhances platelet inhibition in ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention. This approach proves more effective than standard-dose tirofiban in acute settings.
Area of Science:
- Cardiology
- Pharmacology
- Interventional Cardiology
Background:
- Acute ST-segment elevation myocardial infarction (STEMI) requires prompt reperfusion therapy.
- Platelet aggregation plays a crucial role in STEMI pathogenesis and treatment success.
- Antiplatelet therapy is a cornerstone in managing STEMI patients undergoing percutaneous coronary intervention (PCI).
Purpose of the Study:
- To evaluate the efficacy of high-loading-dose tirofiban compared to standard-dose tirofiban and no tirofiban in inhibiting platelet activity.
- To assess the impact of different tirofiban dosing strategies on platelet function in STEMI patients undergoing primary PCI.
Main Methods:
- A randomized controlled trial involving 120 STEMI patients treated with aspirin and clopidogrel.
- Patients were assigned to receive high-dose tirofiban, standard-dose tirofiban, or no tirofiban before angiography.
- Inhibition of platelet aggregation (IPA) was measured using thrombelastography at various time points.
Main Results:
- High-dose tirofiban demonstrated significantly higher IPA at 10 minutes post-infusion compared to standard-dose and control groups.
- At 24 hours post-infusion, both high-dose and standard-dose tirofiban groups showed similar, significantly higher IPA than the control group.
- Maximum amplitude, an indicator of clot strength, was significantly lower in both tirofiban groups compared to the control group.
Conclusions:
- Early administration of high-loading-dose tirofiban, in conjunction with a 600 mg clopidogrel loading dose, is more effective in inhibiting platelet activity.
- This strategy offers superior platelet inhibition compared to standard-dose tirofiban in STEMI patients undergoing primary PCI.
Objective:
To investigate the effect of early high-loading-dose tirofiban on platelet activity for patients with acute ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention.
Methods:
A total of 120 acute STEMI patients were treated with 300 mg aspirin and 600 mg loading dose clopidogrel and randomized to high-dose tirofiban (25 µg/kg bolus followed by 0.15 µg×kg(-1)×min(-1) infusion for 36 hours, n = 40), standard-dose tirofiban (10 µg/kg bolus followed by 0.15 µg×kg(-1)×min(-1) infusion for 36 hours, n = 40) or control (no tirofiban, n = 40) before angiography. Inhibition of platelet aggregation (IPA) was assessed before angiography, at 10 min and 24 hours after tirofiban infusion, and at 12 and 24 hours after stopping tirofiban infusion by the thrombelastography assay.
Results:
There was no significant difference in baseline of IPA between the 3 groups (P > 0.05). IPA was significantly higher in high-dose tirofiban group compared with standard-dose tirofiban and no tirofiban group at 10 minutes after tirofiban infusion [(84.2 ± 12.0)% vs. (67.8 ± 26.8)% and (31.5 ± 21.9)%, all P < 0.01]. At 24 hours after tirofiban infusion, the IPA of high-dose and standard-dose tirofiban was similar [(93.0 ± 9.8)% vs. (88.5 ± 18.1)%, P > 0.05] and was significantly higher than no tirofiban group [(40.4 ± 22.8)%, all P < 0.01]. IPA was similar at 12 and 24 hours after stopping tirofiban use among the 3 groups (all P > 0.05). The maximum amplitude of high-dose tirofiban and standard-dose tirofiban groups at different time points was similar (all P > 0.05), and maximum amplitude in both tirofiban groups was significantly lower than in no tirofiban group at 10 min [(47.2 ± 7.6) mm and (50.0 ± 9.8) mm vs. (57.7 ± 6.5) mm, all P < 0.01] and at 24 hours after stopping tirofiban infusion [(54.6 ± 5.6) mm and (54.3 ± 9.0) mm vs. (59.6 ± 4.0) mm, all P < 0.01].
Conclusion:
Early use of high-loading-dose of tirofiban on top of 600 mg loading dose clopidogrel is more efficient on inhibiting platelet activity than standard dose of tirofiban in patients with acute STEMI undergoing primary primary percutaneous coronary intervention.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Acute Coronary Syndrome I: Introduction
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:30Acute Coronary Syndrome III: Diagnostic Studies